Brainstorm Cell Therapeutics (BCLI) Tops Q4 EPS by 8c; Net R&D Expenses Halved
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
BrainStorm Announces Financial Results for 2015 and Provides Business Update
March 10, 2016 7:42 AM ESTHACKENSACK, N.J. and PETACH TIKVAH, Israel, March 10, 2016 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced financial results for the three months and year ended December 31, 2015.  Brainstorm filed its annual report on Form 10-K reporting the results on March 9, 2016.
"2015 was a year of continued progress and momentum for Brainstorm," stated Chaim Lebovits, Chief Executive Officer of BrainStorm. "We achieved a number of important milestones including completion... More
